Natera Inc. (NTRA)
NASDAQ:NTRA
Want to see NTRA full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.51Last Year’s EPS
-0.74Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong, broad-based operational momentum—robust revenue and unit growth (Q1 revenue $697M, +39% YoY), record oncology volumes (249k MRD tests, +55% YoY), successful new-product launches (Fetal Focus approaching ~200k annualized orders), improved ASPs (Signatera ~$1,250) and raised guidance (revenue guide midpoint reset up >$120M; gross margin guidance to 65% midpoint). Transient headwinds (work-in-process timing, acquisition-related COGS, temporary DSO impact, weather effects, and some coverage/authorization friction) were identified but characterized as short-term or manageable. Given the magnitude and number of positive operational and financial developments and management's upward guide and investment posture, the highlights materially outweigh the lowlights.Company Guidance
Record Revenue Growth
Q1 revenue of $697 million, up 39% year-over-year, driven by strong volume and ASP expansion.
Unit Milestone — 1 Million Units in a Quarter
First quarter in which the company processed 1 million units in a single quarter, demonstrating large-scale volume execution.
Oncology (Signatera) Volume Surge
Processed 249,000 clinical oncology (MRD) units in Q1, a 55% year-over-year increase and ~24,000 units above Q4; implies an MRD run rate of over 1 million tests annually.
Fetal Focus Launch and Women's Health Momentum
Fetal Focus launch exceeding expectations with an approaching annualized run rate of nearly 200,000 orders; core women's health added ~63,000 units quarter-over-quarter (Q4 2025 to Q1 2026).
Pricing and ASP Improvement
Realized ASPs increased across businesses; Signatera ASP reached roughly $1,250 and company reiterated a long-term ASP target of $2,000 per test (which management estimates could translate to ~ $750M incremental revenue at current volumes).
Gross Margin Outperformance and Guidance Raise
Q1 gross margin just under 65%, exceeding prior midpoint guidance (64%); company reset full-year revenue guide up by more than $120 million at the midpoint and raised gross margin guidance to 65% at the midpoint.
Clinical and Publication Momentum
Multiple high-impact data readouts and publications (including bladder cancer data in NEJM and EXPAND trial results), 35 ASCO abstracts planned and broad evidence across tumor types reinforcing Signatera's clinical utility.
Accelerated Trial Enrollment and R&D Investment
Enrollment for oncology trials and FIND CRC is ahead of schedule; company increased R&D expectations by $50 million to pull forward trials and expects FIND CRC enrollment complete by Q3 2026 (PMA path for 2027).
Japan Commercial Opportunity
PMDA approval for Signatera on track for Q2 2026 with launch preparations underway; prior use across 150+ institutions and supportive guidelines could materially expand TAM (Japan CRC opportunity could double Signatera's CRC volume TAM).
Strategic Integration and Product Enhancements
Integration of Foresight Diagnostics progressing well; phased-variant technology and an updated Signatera genome-based assay (with phased variants) planned for clinical availability later this year, with early pharma/research uptake.
NTRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NTRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $219.82 | $194.24 | -11.64% |
Feb 26, 2026 | $216.10 | $208.04 | -3.73% |
Nov 06, 2025 | $198.48 | $199.57 | +0.55% |
Aug 07, 2025 | $141.08 | $151.95 | +7.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Natera Inc. (NTRA) report earnings?
Natera Inc. (NTRA) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Natera Inc. (NTRA) earnings time?
Natera Inc. (NTRA) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NTRA EPS forecast?
NTRA EPS forecast for the fiscal quarter 2026 (Q2) is -0.51.